Osteoprotegerin / OPG Antibody (aa20-37, clone 98A1071)
Mouse Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, IHC-P |
---|---|
Primary Accession | O00300 |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Clone Names | 98A1071 |
Calculated MW | 46kDa |
Dilution | IHC-P (5 µg/ml) |
Gene ID | 4982 |
---|---|
Other Names | Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin, TNFRSF11B, OCIF, OPG |
Target/Specificity | A peptide corresponding to the amino acids 20-37 TQETFPPKYLHYDEETSH of human OPG was used to immunize mice. The specificity was tested on recombinant OPG by western blot analysis. |
Reconstitution & Storage | Long term: -20°C; Short term: +4°C. Avoid repeat freeze-thaw cycles. |
Precautions | Osteoprotegerin / OPG Antibody (aa20-37, clone 98A1071) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | TNFRSF11B |
---|---|
Synonyms | OCIF, OPG |
Function | Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis. |
Cellular Location | Secreted. |
Tissue Location | Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
References
Simonet W.S.,et al.Cell 89:309-319(1997).
Yasuda H.,et al.Endocrinology 139:1329-1337(1998).
Morinaga T.,et al.Eur. J. Biochem. 254:685-691(1998).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Suzuki Y.,et al.Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.